Researchers from the University of Gothenburg, in collaboration with colleagues from University of Glasgow, present data that the drug Entresto (sacubitril/valsartan) which is commonly used for the treatment of cardiac failure leads to a marked reduction in plasma Aβ ratio, a candidate blood test for Alzheimer’s disease (AD).
FS-102 by F-star Therapeutics for Adenocarcinoma Of The Gastroesophageal Junction: Likelihood of Approval
FS-102 is under clinical development by F-star Therapeutics and currently in Phase I for Adenocarcinoma Of The Gastroesophageal Junction.